Related Experiment Videos
Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells
1Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
An adenoviral vector carrying a 2-Kb fragment of the K-ras proto-oncogene inserted in antisense orientation with respect to the cytomegalovirus promoter was constructed and used to infect H460a lung cancer cells (codon 61 K-ras mutation). The gene was efficiently transferred, and a high level of expression of antisense K-ras was achieved. At a multiplicity of infection to achieve 65% transduction of cells, the expression of K-ras protein was reduced by 70% in the lung cancer cell line H460a as compared with cells infected with control vectors or noninfected cells. This reduction produced a 47% inhibition of monolayer growth and a 90% inhibition of colony formation. At a similar level of transduction in the cell line H358 (codon 12 K-ras mutation), a 59% inhibition of monolayer growth compared with control vectors occurred; however the inhibition of H322 cells (wild-type k-ras) growth was no different than control vector infected cells. These data suggest that the adenoviral K-ras H322a antisense vector may have therapeutic potential in tumors in which K-ras is mutated.
Insights
An adenoviral vector effectively reduced K-ras protein in lung cancer cells with mutations. This targeted approach inhibited cancer cell growth and colony formation, showing therapeutic potential for K-ras mutated tumors.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- The K-ras proto-oncogene plays a critical role in cell signaling pathways.
- Mutations in K-ras are frequently observed in various human cancers, including lung cancer.
- Targeting mutated K-ras represents a potential therapeutic strategy.
Purpose of the Study:
- To construct and evaluate an adenoviral vector expressing antisense K-ras.
- To assess the efficacy of this vector in inhibiting K-ras protein expression and cancer cell growth.
- To determine the therapeutic potential of the K-ras antisense vector in different lung cancer cell lines.
Main Methods:
- Construction of an adenoviral vector containing a K-ras fragment in antisense orientation.
- Infection of human lung cancer cell lines (H460a, H358, H322) with the adenoviral vector.
- Quantification of K-ras protein expression using Western blot analysis.
- Assessment of cell proliferation (monolayer growth) and colony formation assays.
Main Results:
- Efficient gene transfer and high expression of antisense K-ras in H460a and H358 cells.
- Significant reduction (70%) in K-ras protein levels in H460a cells (codon 61 mutation).
- Substantial inhibition of monolayer growth (47%) and colony formation (90%) in H460a cells.
- Significant inhibition of monolayer growth (59%) in H358 cells (codon 12 mutation).
- No significant inhibition of growth observed in H322 cells with wild-type K-ras.
Conclusions:
- Adenoviral K-ras antisense vector effectively reduces K-ras protein expression in mutated lung cancer cells.
- The vector demonstrates significant anti-proliferative effects on lung cancer cells harboring K-ras mutations.
- This approach holds therapeutic promise for K-ras-mutated tumors, warranting further investigation.